The MDMA Comedown: Why It Happens and What Helps

The dip that lands one to three days after MDMA is acute serotonin depletion, and for occasional use at moderate doses it resolves inside a week. MDMA forces a large release of serotonin out of nerve terminals, and the brain needs 24 to 72 hours or more to build the supply back. Nothing is broken. Something is temporarily empty.

That is the reassuring version, and it is true for most people. Heavier and more frequent use makes the dip deeper and longer, which is the part worth taking seriously.

Why it empties

MDMA reverses the serotonin transporter, pushing serotonin out into the synapse instead of letting it be reabsorbed. Dopamine and norepinephrine come along too, but the serotonin effect drives both the high and the crash. Animal work suggests 80 to 90 percent of stored serotonin gets released.

Refilling means resynthesising serotonin from dietary tryptophan, via 5-HTP, and that takes time you cannot shorten much. In animal models the acute depletion starts resolving within 24 to 48 hours, with full normalisation taking a week or longer. There is no way to measure this directly in a living human, but subjective mood recovery tracks the same window closely enough to be useful.

The second mechanism is oxidative stress. MDMA’s metabolism produces reactive metabolites and promotes hydroxyl radical formation in serotonin-dense regions: striatum, hippocampus, frontal cortex. That is the entire theoretical basis for the antioxidant supplements people take around a roll, and the evidence for it comes almost wholly from rodents at doses far above anything recreational.

Worth saying plainly, because people frighten themselves here: the imaging evidence for lasting structural damage from moderate use is weak. Mueller’s 2016 systematic review found no convincing evidence of structural or functional brain alteration in users below roughly 50 lifetime occasions. The severe serotonergic findings that make headlines come from heavy users with hundreds of sessions.

The afterglow can fool you

Plenty of people feel good first. A 12 to 24 hour stretch of residual warmth, emotional openness and mild euphoria is common enough to have its own name. Part of it looks oxytocinergic: a 2009 human study found oxytocin rose significantly during MDMA use and correlated with prosocial feeling, and oxytocin outlasts MDMA’s acute serotonin effects.

The afterglow is real. It is not recovery. Serotonin is already declining underneath it, and the comedown tends to arrive as the afterglow fades, which is why day two catches people off guard.

What the week looks like

Rough, for occasional use at a moderate dose. Dose, frequency, metabolism and sleep all move it.

• Hours 0 to 12. The drug wears off. Residual stimulation, sleep hard to come by.
• Day 1. Often the easiest day. The afterglow can carry you.
• Days 2 to 3. The bottom. Fatigue, flat mood, low motivation, irritability or anxiety, poor sleep.
• Days 4 to 7. Gradual climb back. Most occasional users are at baseline by the end of the week.
• Past two weeks. Not a comedown any more. See a doctor.

Frequent use, more than monthly, stops the recovery from completing before the next session starts, and comedowns get worse over time. That is the pharmacology behind the one to three month spacing guideline, not a moral preference.

5-HTP: wait 24 hours, and mean it

5-HTP is a direct serotonin precursor, and the reasoning for taking it afterwards is sound. Stores are low, so supply the raw material.

Do not take it until at least 24 hours after your last MDMA dose.

MDMA’s half-life is roughly 7 to 8 hours, and its active metabolite MDA runs longer. Serotonin-releasing activity persists past the point where you stop feeling anything. Adding precursor to a brain that is still releasing serotonin is how people give themselves serotonin syndrome: agitation, muscle rigidity, racing heart, rising temperature. The 24-hour gap exists to let the releasing activity stop before the supply arrives.

Some resources suggest pairing 5-HTP with carbidopa, a peripheral decarboxylase inhibitor from Parkinson’s treatment, so that more 5-HTP reaches the brain instead of being converted in the gut. The pharmacology is accurate and that is exactly the problem. It sharply raises serotonin syndrome risk. Do not combine 5-HTP with carbidopa without a prescribing physician.

Plain 5-HTP at 50 to 100 mg, 24 hours or more out, is the community standard. Evidence tier: mechanistic and anecdotal. No published trial has tested 5-HTP for MDMA comedown. It is low-risk at that dose and it may help. It is not a cure. Nutricost 5-HTP 100mg is a plain formulation without additives.

The supplements, honestly

Every antioxidant in the standard rave protocol rests on the same kind of study: a rat, an injection, and a dose that does not translate. That does not make them worthless. It means you should know what you are buying.

Alpha lipoic acid. Aguirre and colleagues found in 1999 that pre-treating rats with 100 mg/kg of injected ALA fully prevented MDMA-induced serotonergic deficits in frontal cortex, striatum and hippocampus. Scaled to a 75 kg human that is roughly 7,500 mg, injected, against oral supplements with much lower bioavailability. There are no human trials. The mechanism is plausible and ALA is safe at ordinary doses. R-ALA is the biologically active isomer and absorbs better, so it’s the form to use. Nutricost R-Alpha Lipoic Acid is a clean 100 mg capsule.

Vitamin C. Shankaran, Yamamoto and Gudelsky reported in 2001 that ascorbic acid suppressed MDMA-induced hydroxyl radical formation in rat striatum and blunted serotonin depletion. Same limitations: rodent, injected, high dose. Human efficacy for MDMA recovery is not established. What vitamin C has going for it is that 1 to 2 g is cheap, well tolerated and hard to get wrong, so the risk-benefit sits in its favour even on thin evidence. Take it with food. Nature Made Vitamin C 1000mg is USP verified.

Magnesium glycinate. No trial has tested magnesium for MDMA bruxism, but it’s a calcium channel blocker and muscle relaxant, and the jaw clenching is real. For the comedown specifically, the case is about sleep: magnesium modulates NMDA receptors and supports sleep quality in the general population, and poor sleep is what turns a manageable comedown into a bad week. Glycinate is among the more bioavailable forms. Doctor’s Best High Absorption Magnesium Glycinate is the chelated version.

Evidence tier for all three: community practice with animal pharmacology behind it, not clinical proof.

The things that actually work

The behavioural side has better mechanisms and worse marketing.

Sleep. The single most effective thing available, and the one people skip. Slow-wave sleep supports neurochemical recovery, and MDMA disrupts sleep architecture even when you feel exhausted. Get to bed at a sane hour for the following few nights even if the sleep itself is mediocre.

Eat, whether or not you want to. Tryptophan comes from food and your brain cannot rebuild serotonin without it. Appetite is usually suppressed for a day or more. Eat protein anyway: eggs, meat, dairy, legumes.

Electrolytes, not just water. MDMA triggers antidiuretic hormone release, and a night of sweating depletes electrolytes. Plain water alone is the wrong replacement.

No alcohol. It’s a depressant, it wrecks sleep, and it is one of the most reliable ways to turn a mild comedown into a genuinely bad week.

No second session next weekend. The spacing guideline is the same pharmacology as the comedown itself. Using before recovery finishes compounds the depletion, and it’s how people end up with the version of this that lasts.

A walk helps a little through tryptophan hydroxylase activity. A hard workout does not, because it adds oxidative stress during the window you are trying to protect.

When it isn’t a comedown any more

Low mood after MDMA is expected. Low mood lasting past two weeks is not, and it deserves a doctor rather than another supplement.

Persistent anhedonia, withdrawal from people, or anxiety at that distance from the last dose can mean prolonged receptor down-regulation from heavy use, an underlying depression that MDMA unmasked or worsened, or a pattern of use that has been outrunning recovery for long enough that the baseline itself has shifted.

Be honest with the doctor about what you took. Accurate history is what makes the evaluation useful, and the clinical conversation around this drug has changed: the MAPS Phase 3 trials published in 2021 and 2023 put MDMA-assisted therapy on the table as a PTSD treatment, and many clinicians will engage with the subject seriously now rather than shutting it down.

No pill substitutes for sleep, food and time. The comedown is predictable, and the three things that reliably shorten it are the three that nobody wants to hear.

For the wider picture, see the MDMA guide and the spacing guide. Before mixing anything, check the interaction checker.

Sources

PMID 26746590 | PMID 19562632 | PMID 18520604 | PMID 10619665 | PMID 11170222 | PMID 33972795 | PMID 37709999